{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:38:18Z","timestamp":1784043498883,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["5KL2TR001879-08"],"award-info":[{"award-number":["5KL2TR001879-08"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jhepr.2024.101264","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T02:08:43Z","timestamp":1731031723000},"page":"101264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Human GM-CSF\/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1506-232X","authenticated-orcid":false,"given":"Kelley","family":"Weinfurtner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1338-2517","authenticated-orcid":false,"given":"David","family":"Tischfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"McClung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Crainic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma E.","family":"Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erena Tuzneen","family":"Supan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Nadolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6400-4321","authenticated-orcid":false,"given":"Stephen J.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3839-336X","authenticated-orcid":false,"given":"David E.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8783-0661","authenticated-orcid":false,"given":"Terence P.F.","family":"Gade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2024.101264_bib1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhepr.2024.101264_bib2","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2024.101264_bib3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jhepr.2024.101264_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhepr.2024.101264_bib5","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101264_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/jamaoncol.2020.3381","article-title":"The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a Review","volume":"7","author":"Pinter","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2024.101264_bib7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhepr.2024.101264_bib8","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastro"},{"key":"10.1016\/j.jhepr.2024.101264_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2024.101264_bib10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41575-018-0033-6","article-title":"Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research","volume":"15","author":"Brown","year":"2018","journal-title":"Nat Rev Gastro Hep"},{"key":"10.1016\/j.jhepr.2024.101264_bib11","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/2159-8290.CD-18-0044","article-title":"Mouse models for cancer immunotherapy research","author":"Olson","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101264_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101960","article-title":"Human and mouse PD-L1: similar molecular structure, but different druggability profiles","volume":"24","author":"Magiera-Mularz","year":"2020","journal-title":"iScience"},{"issue":"8","key":"10.1016\/j.jhepr.2024.101264_bib13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"B-catenin activation promotes immune escape and resistance to anti-PD-1 in hepatocellular carcinoma","volume":"9","author":"Ruiz de Galarreta","year":"2019","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101264_bib14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/pcmr.12591","article-title":"UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model","volume":"30","author":"Wang","year":"2017","journal-title":"Pigment Cel Melanoma Res."},{"key":"10.1016\/j.jhepr.2024.101264_bib15","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhepr.2024.101264_bib16","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101264_bib17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc.2016.140","article-title":"Interrogating open issues in cancer precision medicine with patient-derived xenografts","volume":"17","author":"Byrne","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhepr.2024.101264_bib18","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/hep4.1365","article-title":"Hepatocellular carcinoma xenografts established from needle biopsies preserve the characteristics of the originating tumors","volume":"3","author":"Blumer","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2024.101264_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47104-9","article-title":"Establishment of hepatocellular carcinoma patient-derived xenografts from image-guided percutaneous biopsies","volume":"9","author":"Tischfield","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2024.101264_bib20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4049\/jimmunol.169.1.204","article-title":"Functional human T lymphocyte development from cord blood CD34+ cells in nonobese diabetic\/Shi-scid, IL-2 receptor null mice","volume":"169","author":"Yahata","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhepr.2024.101264_bib21","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhepr.2024.101264_bib22","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nri3311","article-title":"Humanized mice for immune system investigation: progress, promise and challenges","volume":"12","author":"Shultz","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101264_bib23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2249.2009.03933.x","article-title":"Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex","volume":"157","author":"King","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhepr.2024.101264_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2015.06.006","article-title":"Chronic graft-versus-host-disease\u00a0in CD34(+)-humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease","volume":"62","author":"Sonntag","year":"2015","journal-title":"J\u00a0Autoimmun"},{"issue":"12","key":"10.1016\/j.jhepr.2024.101264_bib25","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.4049\/jimmunol.1103660","article-title":"Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD\/SCID\/IL2ryKO mice","volume":"188","author":"Tanaka","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhepr.2024.101264_bib26","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1136\/gutjnl-2017-315201","article-title":"Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy","volume":"67","author":"Zhao","year":"2018","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.jhepr.2024.101264_bib27","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2010-08-301507","article-title":"Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2R-gamma(null) humanized mice","volume":"117","author":"Bilerbeck","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jhepr.2024.101264_bib28","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.3389\/fimmu.2020.02082","article-title":"The tumor milieu promotes functional human tumor-resident plasmacytoid dendritic cells in humanized mouse models","volume":"11","author":"Maser","year":"2020","journal-title":"Front Immunol"},{"issue":"18","key":"10.1016\/j.jhepr.2024.101264_bib29","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1182\/blood-2009-10-249326","article-title":"Engraftment of human hematopoietic stem cells is more efficient in female NOD\/SCID\/IL-2Rgc-null recipients","volume":"115","author":"Notta","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jhepr.2024.101264_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.607282","article-title":"Testing cancer immunotherapy in a human immune system mouse model: correlating treatment response to human chimerism, therapeutic variables, and immune cell phenotypes","volume":"12","author":"Marin-Jimenez","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2024.101264_bib32","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/hep.31812","article-title":"Analysis and validation of human targets and treatments using a hepatocellular carcinoma immune humanized mouse model","volume":"74","author":"Zhao","year":"2021","journal-title":"Hepatol"},{"key":"10.1016\/j.jhepr.2024.101264_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.rvsc.2020.12.003","article-title":"Pathology of macrophage activation syndrome in humanized NSGS mice","volume":"134","author":"Tarrant","year":"2021","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.jhepr.2024.101264_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/03009858231222216","article-title":"Humanization with CD34-positive hematopoetic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice","author":"Willis","year":"2024","journal-title":"Vet Pathol"},{"key":"10.1016\/j.jhepr.2024.101264_bib35","unstructured":"Comparison guide: huNOG-EXL, NSG-SGM3, and MISTRG. Taconic biosciences. https:\/\/www.taconic.com\/resources\/comparison-guide-hunog-exl-nsg-sgm3-and-mistrg. Accessed 4\/24\/24."},{"issue":"4","key":"10.1016\/j.jhepr.2024.101264_bib36","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nbt.2858","article-title":"Development and function of human innate immune cells in a humanized mouse model","volume":"32","author":"Rongvaux","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"9","key":"10.1016\/j.jhepr.2024.101264_bib37","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0301-472X(99)00078-8","article-title":"Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow","volume":"27","author":"Holyoake","year":"1999","journal-title":"Exp Hematol"},{"issue":"10","key":"10.1016\/j.jhepr.2024.101264_bib38","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.humimm.2009.06.005","article-title":"Comparision of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid\/\u03b3c\u2212\/\u2212, Balb\/c-Rag1\u2212\/\u2212\u03b3c\u2212\/\u2212, and C.B-17-scid\/bg immunodeficient mice","volume":"70","author":"Lepus","year":"2009","journal-title":"Hum Immunol"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101264_bib39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/bloodadvances.2018023887","article-title":"Human hematopoietic stem cell maintenance and myeloid cell development in next-generation humanized mouse models","volume":"3","author":"Sippel","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jhepr.2024.101264_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.573406","article-title":"Different human immune lineage compositions are generated in non-conditioned NBSGW mice depending on HSPC source","volume":"11","author":"Hess","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101264_bib41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/iid3.317","article-title":"Humanized mouse model: hematopoietic stem cell transplantation and tracking using short tandem repeat technology","volume":"8","author":"Walcher","year":"2020","journal-title":"Immun Inflamm Dis"},{"issue":"32","key":"10.1016\/j.jhepr.2024.101264_bib42","doi-asserted-by":"crossref","first-page":"13218","DOI":"10.1073\/pnas.1109769108","article-title":"Transgenic expression of human signal regulatory protein alpha in Rag2\u2212\/\u2212\u03b3c\u2212\/\u2212 mice improves engraftment of human hematopoietic cells in humanized mice","volume":"108","author":"Strowig","year":"2011","journal-title":"PNAS"},{"issue":"14","key":"10.1016\/j.jhepr.2024.101264_bib43","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood-2015-10-676452","article-title":"Peripheral blood CD34+ cells engraft in human cytokine knock-in mice","volume":"128","author":"Saito","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jhepr.2024.101264_bib44","article-title":"Autologus humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment","volume":"11","author":"Chiorazzi","year":"2023","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:28:28Z","timestamp":1741638508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555924002684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2589555924002684"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101264","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.10.05.561117","asserted-by":"object"}]},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human GM-CSF\/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101264"}}